구조모아 (StructureMoa)항암 chemical structure spider web
방문프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | telisotuzumab vedotin (Emrelis, ABBV-399, Teliso-V, telisotuzumab-vedotin-tllv) AbbVie·c-Met 12 trials·t½ ADC in the range of days; free MMAE shorter |
|---|---|
Overview Program | Emrelis (telisotuzumab vedotin) |
Overview Company | AbbVie |
Overview Modality | ADC |
Overview Target | c-Met |
Overview Indication | Previously treated locally advanced or metastatic non-squamous NSCLC with high c-Met protein overexpression |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Selects high c-Met protein overexpression by IHC, not MET gene mutation. That split is the first row versus MET TKIs. |
Positioning Known limitation | c-Met down-regulation, MMAE efflux, and histologic transformation. |
Positioning Development positioning | Only approved c-Met ADC; confirmatory TeliMET NSCLC-01 versus docetaxel is ongoing. |
Technology Payload | MMAE (microtubule inhibitor) |
Technology Linker | Cleavable vc linker, vedotin chemistry |
MoA Mechanism | Anti-c-Met antibody binds and internalizes; the protease-cleavable linker releases MMAE, which disrupts microtubules and kills the cell plus neighbors via bystander diffusion. |
MoA Biomarker | VENTANA MET (SP44) companion diagnostic. High overexpression is ≥50% of cells with 3+ staining, not MET exon 14 skipping. |
PK/PD Half-life | ADC in the range of days; free MMAE shorter |
PK/PD Animal (cat.) | Human |
Toxicology Major finding | Peripheral neuropathy, fatigue, decreased appetite, and peripheral edema are common. Grade 3–4 lab signals include lymphopenia and transaminase rises. |
Toxicology CRS | N/A |
Clinical Safety signal | Peripheral neuropathy, fatigue, decreased appetite, and peripheral edema are common. Grade 3–4 lab signals include lymphopenia and transaminase rises. |
Clinical Selected reported efficacy | ORR 35% |
Clinical Reported ORR | 35% |
Clinical Result source | LUMINOSITY (NCT03539536) |
Clinical Program phase | APPROVED |
Clinical Trial ref | NCT03539536 |
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | telisotuzumab vedotin (Emrelis, ABBV-399, Teliso-V, telisotuzumab-vedotin-tllv) AbbVie·c-Met 12 trials·t½ ADC in the range of days; free MMAE shorter |
|---|---|
Overview Program | Emrelis (telisotuzumab vedotin) |
Overview Company | AbbVie |
Overview Modality | ADC |
Overview Target | c-Met |
Overview Indication | Previously treated locally advanced or metastatic non-squamous NSCLC with high c-Met protein overexpression |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Selects high c-Met protein overexpression by IHC, not MET gene mutation. That split is the first row versus MET TKIs. |
Positioning Known limitation | c-Met down-regulation, MMAE efflux, and histologic transformation. |
Positioning Development positioning | Only approved c-Met ADC; confirmatory TeliMET NSCLC-01 versus docetaxel is ongoing. |
Technology Payload | MMAE (microtubule inhibitor) |
Technology Linker | Cleavable vc linker, vedotin chemistry |
MoA Mechanism | Anti-c-Met antibody binds and internalizes; the protease-cleavable linker releases MMAE, which disrupts microtubules and kills the cell plus neighbors via bystander diffusion. |
MoA Biomarker | VENTANA MET (SP44) companion diagnostic. High overexpression is ≥50% of cells with 3+ staining, not MET exon 14 skipping. |
PK/PD Half-life | ADC in the range of days; free MMAE shorter |
PK/PD Animal (cat.) | Human |
Toxicology Major finding | Peripheral neuropathy, fatigue, decreased appetite, and peripheral edema are common. Grade 3–4 lab signals include lymphopenia and transaminase rises. |
Toxicology CRS | N/A |
Clinical Safety signal | Peripheral neuropathy, fatigue, decreased appetite, and peripheral edema are common. Grade 3–4 lab signals include lymphopenia and transaminase rises. |
Clinical Selected reported efficacy | ORR 35% |
Clinical Reported ORR | 35% |
Clinical Result source | LUMINOSITY (NCT03539536) |
Clinical Program phase | APPROVED |
Clinical Trial ref | NCT03539536 |
추천 비교
추천 비교